FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129880070> ?p ?o ?g. }

• W2129880070 endingPage "1644" @default.
• W2129880070 startingPage "1636" @default.
• W2129880070 abstract "Abstract The recombinant fusion protein aflibercept (ziv-aflibercept in the United States) binds VEGF-A, VEGF-B, and placental growth factor (PlGF). The monoclonal antibody bevacizumab binds VEGF-A. Recent studies hypothesized that dual targeting of VEGF/PlGF is more beneficial than targeting either ligand. We compared activity of aflibercept versus bevacizumab in 48 patient-derived xenograft (PDX) colorectal cancer models. Nude mice engrafted subcutaneously with PDX colorectal cancer tumors received biweekly aflibercept, bevacizumab, or vehicle injections. Differential activity between aflibercept and bevacizumab, determined by mouse (m), human (h), VEGF-A, and PlGF levels in untreated tumors, was measured. Aflibercept induced complete tumor stasis in 31 of 48 models and bevacizumab in 2 of 48. Based on statistical analysis, aflibercept was more active than bevacizumab in 39 of 48 models; in 9 of 39 of these models, bevacizumab was considered inactive. In 9 of 48 remaining models, aflibercept and bevacizumab had similar activity. Tumor levels of hVEGF-A (range 776–56,039 pg/mg total protein) were ∼16- to 1,777-fold greater than mVEGF-A (range 8–159 pg/mg total protein). Tumor levels of mPlGF (range 104–1,837 pg/mg total protein) were higher than hPlGF (range 0–543 pg/mg total protein) in 47 of 48 models. Tumor cells were the major source of VEGF; PlGF was primarily produced by tumor stroma. Because tumor levels of hVEGF-A were far greater than mVEGF-A, bevacizumab's inability to bind mVEGF-A is unlikely to explain higher and more consistent aflibercept activity. Neutralizing PlGF and VEGFR-1 activation may be a factor and should be investigated in future studies. In these colorectal cancer PDX models, aflibercept demonstrated greater antitumor activity than bevacizumab. Mol Cancer Ther; 13(6); 1636–44. ©2014 AACR." @default.
• W2129880070 created "2016-06-24" @default.
• W2129880070 creator A5009420846 @default.
• W2129880070 creator A5012837184 @default.
• W2129880070 creator A5034065748 @default.
• W2129880070 creator A5044650603 @default.
• W2129880070 creator A5050555159 @default.
• W2129880070 creator A5052002848 @default.
• W2129880070 creator A5053547911 @default.
• W2129880070 creator A5085041670 @default.
• W2129880070 creator A5088990072 @default.
• W2129880070 date "2014-06-01" @default.
• W2129880070 modified "2023-10-17" @default.
• W2129880070 title "Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer" @default.
• W2129880070 cites W1520183139 @default.
• W2129880070 cites W1875554126 @default.
• W2129880070 cites W1911505241 @default.
• W2129880070 cites W1972328572 @default.
• W2129880070 cites W1980725734 @default.
• W2129880070 cites W1981421409 @default.
• W2129880070 cites W1985043086 @default.
• W2129880070 cites W1994329038 @default.
• W2129880070 cites W1998425221 @default.
• W2129880070 cites W1998754600 @default.
• W2129880070 cites W2003801328 @default.
• W2129880070 cites W2011416603 @default.
• W2129880070 cites W2011582582 @default.
• W2129880070 cites W2016164151 @default.
• W2129880070 cites W2029763523 @default.
• W2129880070 cites W2041251610 @default.
• W2129880070 cites W2049474645 @default.
• W2129880070 cites W2051869883 @default.
• W2129880070 cites W2054712910 @default.
• W2129880070 cites W2057623977 @default.
• W2129880070 cites W2059889603 @default.
• W2129880070 cites W2074195384 @default.
• W2129880070 cites W2076424556 @default.
• W2129880070 cites W2077801037 @default.
• W2129880070 cites W2081633887 @default.
• W2129880070 cites W2083802683 @default.
• W2129880070 cites W2089955307 @default.
• W2129880070 cites W2093044616 @default.
• W2129880070 cites W2095374934 @default.
• W2129880070 cites W2113272754 @default.
• W2129880070 cites W2115735904 @default.
• W2129880070 cites W2119281341 @default.
• W2129880070 cites W2122730895 @default.
• W2129880070 cites W2142167347 @default.
• W2129880070 cites W2144170022 @default.
• W2129880070 cites W2146026405 @default.
• W2129880070 cites W2147834058 @default.
• W2129880070 cites W2147873693 @default.
• W2129880070 cites W2154502317 @default.
• W2129880070 cites W2166788033 @default.
• W2129880070 cites W2793323124 @default.
• W2129880070 doi "https://doi.org/10.1158/1535-7163.mct-13-0753" @default.
• W2129880070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24688047" @default.
• W2129880070 hasPublicationYear "2014" @default.
• W2129880070 type Work @default.
• W2129880070 sameAs 2129880070 @default.
• W2129880070 citedByCount "49" @default.
• W2129880070 countsByYear W21298800702014 @default.
• W2129880070 countsByYear W21298800702015 @default.
• W2129880070 countsByYear W21298800702016 @default.
• W2129880070 countsByYear W21298800702017 @default.
• W2129880070 countsByYear W21298800702018 @default.
• W2129880070 countsByYear W21298800702019 @default.
• W2129880070 countsByYear W21298800702020 @default.
• W2129880070 countsByYear W21298800702021 @default.
• W2129880070 countsByYear W21298800702022 @default.
• W2129880070 countsByYear W21298800702023 @default.
• W2129880070 crossrefType "journal-article" @default.
• W2129880070 hasAuthorship W2129880070A5009420846 @default.
• W2129880070 hasAuthorship W2129880070A5012837184 @default.
• W2129880070 hasAuthorship W2129880070A5034065748 @default.
• W2129880070 hasAuthorship W2129880070A5044650603 @default.
• W2129880070 hasAuthorship W2129880070A5050555159 @default.
• W2129880070 hasAuthorship W2129880070A5052002848 @default.
• W2129880070 hasAuthorship W2129880070A5053547911 @default.
• W2129880070 hasAuthorship W2129880070A5085041670 @default.
• W2129880070 hasAuthorship W2129880070A5088990072 @default.
• W2129880070 hasBestOaLocation W21298800702 @default.
• W2129880070 hasConcept C121608353 @default.
• W2129880070 hasConcept C126322002 @default.
• W2129880070 hasConcept C143998085 @default.
• W2129880070 hasConcept C167734588 @default.
• W2129880070 hasConcept C2776694085 @default.
• W2129880070 hasConcept C2777025900 @default.
• W2129880070 hasConcept C2777802072 @default.
• W2129880070 hasConcept C2778749236 @default.
• W2129880070 hasConcept C502942594 @default.
• W2129880070 hasConcept C526805850 @default.
• W2129880070 hasConcept C71924100 @default.
• W2129880070 hasConcept C98274493 @default.
• W2129880070 hasConceptScore W2129880070C121608353 @default.
• W2129880070 hasConceptScore W2129880070C126322002 @default.
• W2129880070 hasConceptScore W2129880070C143998085 @default.
• W2129880070 hasConceptScore W2129880070C167734588 @default.

• next